SAN FRANCISCO–(BUSINESS WIRE)–InterVenn Biosciences, the leader in glycoproteomics, today announced that it has named Brian Hogan as Chief Financial Officer. In this strategic role, Brian will have responsibility for all aspects of finance and investor relations as the company accelerates its growth strategy to scale the company’s capabilities, operations and partnerships. This newly created position expands the executive leadership team to support the company’s AI-powered glycoproteomics-based approach enabling clinical insights through the development of biomarkers, diagnostics and therapeutics across oncology applications and an expanding spectrum of diseases.
“I am delighted to welcome Brian to InterVenn as our CFO,” said Aldo Carrascoso, CEO of InterVenn. “The expansion of InterVenn’s executive leadership team with this critical new hire is a significant step forward toward our ability to take the company to the next level. With his extensive experience in the life sciences industry, Brian’s leadership within the financial function will be a driving force to scale our organization and help accelerate the growth of our innovative pipeline of liquid biopsy products and clinical solutions.”
“I’m excited to join InterVenn on its mission to positively impact people’s lives through its breakthrough innovation that targets life-threatening disease,” said Brian Hogan, CFO of InterVenn. “InterVenn is uniquely positioned in the liquid biopsy, diagnostics and healthcare space. Following a highly successful Series C funding round, this is a time of significant opportunity for the company.”
Brian brings over 20 years of finance and leadership experience in public and private companies to InterVenn. Prior to joining InterVenn, Brian was the CFO at Clear Labs. His previous roles also included: SVP, Global Finance and Accounting at Portola; CFO at Adicet Bio; and VP, Finance at Genomic Health. He earned a bachelor’s degree in Business Administration with a concentration in Finance from California State University, Sacramento, and an MBA from Saint Mary’s College of California.
InterVenn is in the process of reshaping the future of healthcare by opening up a whole new dimension of biology called the glycoverse, which includes the glycoproteome in addition to glycolipids and glyco-RNA. The glycoproteome holds the keys to profound new insights into new therapies and diagnostics for a variety of diseases. Pioneering a new AI-powered approach to predict, prevent and observe disease progression in real time, InterVenn’s glycoproteomics solutions unveil the potential of the glycoproteome with precision, speed and scalability for the first time in history – an advancement in decoding that is on par with the ability to sequence the human genome.
For more information, go to: www.intervenn.com.
InterVenn Biosciences has developed a proprietary glycoproteomic biomarker discovery and interrogation platform based on artificial intelligence-empowered mass spectrometry for next-gen precision medicine. The company is working on developing novel predictive tests in a range of indications, including ovarian, pancreatic, liver, prostate, lung, kidney and other cancers, as well as on tests for treatment response prediction and monitoring of treatment efficacy, and disease progression. https://intervenn.com